Skip to main content
. Author manuscript; available in PMC: 2024 Jun 1.
Published in final edited form as: Pediatr Blood Cancer. 2023 Mar 28;70(6):e30319. doi: 10.1002/pbc.30319

Figure 1: Self-Reported Knowledge About Gene Therapy, Bone Marrow Transplantation, and Hydroxyurea as Potential Treatments for Sickle Cell Disease.

Figure 1:

Using a five-point Likert Scale, participants were asked to report their knowledge of two potentially curative treatments for Sickle Cell Disease (SCD) alongside a commonly available disease-modifying therapy (Hydroxyurea). Self-reported knowledge about Hydroxyurea therapy for SCD was significantly greater than for either bone marrow transplantation or gene therapy (P < 0.0001, for both comparisons).